EpiCept Files for AmiKet™ Fast Track Designation

EpiCept Corporation announced that it has filed for Fast Track designation for AmiKet, their new topical cream to be used in the treatment of chemotherapy-induced peripheral neuropathy. The Fast Track program, created by the FDA, is designed to facilitate development and expedite review of drugs intended to treat serious or life-threatening conditions and address unmet medical needs. Using the Fast Track program can reduce the standard reivew time by the FDA by half. The National Cancer Institute sponsored the the study evaluating the efficacy and safety of AmiKet. READ MORE

Source: 4-Traders